Summary

• The UK government, Innovate UK, and Lilly are backing 12 obesity care projects with up to £85 million in grant funding.
• The programme includes AI assisted triage, apps, WhatsApp-based advice, neighbourhood hubs, and new routes into NHS support.
• The implementation test will be whether digital access reduces pressure and inequality without fragmenting care.

Department for Science, Innovation and Technology, the Department of Health and Social Care, Innovate UK, and Lilly are backing 12 projects intended to change how people access obesity care across the UK.

The Obesity Pathway Innovation Programme will provide up to £85 million in grant funding, with up to £50 million from government and up to £35 million from pharmaceutical company Eli Lilly and Company. The projects include apps, round the clock advice through WhatsApp, AI assisted triage, neighbourhood hubs, and online referral routes.

The programme is aimed particularly at underserved communities and is expected to run until March 2029. Government examples include AI assisted triage in Norfolk, Suffolk, and north east Essex; WhatsApp-based support for families in Kent; neighbourhood hubs in Leicester and Northamptonshire; self-referral in Northern Ireland; and a clearer route into NHS weight management support in Wales.

Obesity care is a difficult setting for digital transformation. Access is uneven, clinical pathways vary, demand is high, and the support people need often crosses lifestyle advice, psychological support, medication, social prescribing, community services, and specialist care. A digital front door can simplify navigation only if the services behind it are coordinated and properly governed.

Digital health meets service redesign

The AI element should be treated carefully. AI assisted triage could help match people to appropriate support more quickly, reduce administrative burden, and make scarce clinical capacity easier to allocate. It could also create new failure points if assessment tools are poorly validated, data quality is weak, or users are directed towards unsuitable services.

Those risks are sharper because the programme is aimed at groups already less well served by existing systems, including deprived, Black, South Asian, and rural communities. Digital health projects can widen access when they are designed around barriers such as travel, language, working patterns, stigma, and fragmented referrals. They can also widen inequality when they assume smartphone access, digital confidence, health literacy, and trust in automated systems.

The involvement of Lilly adds another layer of scrutiny. The government says Lilly was involved in designing guidelines and is contributing arms length grant funding, but was not involved in assessment, ranking, interview, or selection of successful applications. That distinction will be tested in public debate because obesity care is increasingly bound up with pharmaceutical treatments, demand management, and questions about the role of drug companies in service pathways.

The programme could still generate useful evidence. NHS organisations need better ways to manage long term conditions outside hospital settings, and obesity care is a field where prevention, early support, clinical treatment, and community provision are deeply connected. If the projects can show faster access, better matching to support, improved outcomes, and lower pressure on front line services, they could inform wider digital pathway design.

The challenge is measurement. App downloads, triage volumes, and contact numbers will not be enough. Useful evidence will involve outcomes, equity, patient experience, clinician workload, safeguarding, escalation, and whether people can move between digital and in-person support without being lost in the system.

The £85 million programme is not simply a health technology funding announcement. It is a test of whether AI and digital access tools can be embedded into public service delivery without turning care into a maze of apps, chat interfaces, and disconnected pilots.